Congress extends diabetes research funding through 2030
H.R. 5461 — Special Diabetes Program Reauthorization Act of 2025 · Filed by Diana DeGette (D-CO) · 49 cosponsors · Introduced Sep 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends federal funding for the Special Diabetes Program for Type I diabetes by appropriating $160 million per year for fiscal years 2026–2030. The program provides grants to health centers and researchers to improve diabetes care and prevention. The bill simply adds a new funding line to an existing program authorization.
Why we flagged it
The bill is a straightforward extension of existing federal funding for a diabetes research and care program. It adds appropriations to an established public health initiative with no structural changes or private carve-outs.
Who it affects
The bill extends dedicated federal funding for a public health program that directly supports Type I diabetes research, care coordination, and prevention services. Citizens with Type I diabetes and underserved communities benefit from sustained program resources.
Named in the bill
Special Diabetes Program for Type I diabetes, Public Health Service Act, Section 330B(b)(2), Health centers, Diabetes researchers
Where it stands
49 cosponsors: 35 Democrats, 14 Republicans.
- Sep 18, 2025 — Introduced · Congress.gov: “Introduced in House”
- Sep 18, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Dec 2025 to Dec 2025. Those filings disclosed $290,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Diana DeGette, the sponsor, reported $915,500 in PAC receipts in the 2026 cycle.
- Breakthrough T1d (formerly Known As Jdrf Intl.) — $290,000 on 1 filing
Lobbying Disclosure Act filings through Jan 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (498 characters) on Jun 3, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Dec 2025. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jan 20, 2026 · page rendered 2026-10-20.
“Congress extends diabetes research funding through 2030” QuorumCivic. https://share.quorumcivic.app/bill/119/hr5461 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.